학술논문
'학술논문'
에서 검색결과 7건 | 목록
1~10
Academic Journal
Flavia L. Lombardo; Stefania Spila Alegiani; Flavia Mayer; Marta Cipriani; Maria Lo Giudice; Albert Christian Ludolph; Christopher J. McDermott; Philippe Corcia; Philip Van Damme; Leonard H. Van den Berg; Orla Hardiman; Gabriele Nicolini; Nicola Vanacore; Brian Dickie; Alberto Albanese; Maria Puopolo; TUDCA-ALS Study Group
Trials, Vol 24, Iss 1, Pp 1-11 (2023)
Academic Journal
Alberto Albanese; Albert Christian Ludolph; Christopher J. McDermott; Philippe Corcia; Philip Van Damme; Leonard H. Van den Berg; Orla Hardiman; Gilberto Rinaldi; Nicola Vanacore; Brian Dickie; TUDCA-ALS Study Group; Paolo Tornese; Antoniangela Cocco; Maria Lo Giudice; Michela Matteoli; Eliana Lauranzano; Maria Luisa Malosio; Chiara Adriana Elia; Flavia Lombardo; Flavia Mayer; Maria Puopolo; Stefania Spila Alegiani; Adriano Chiò; Umberto Manera; Cristina Moglia; Andrea Calvo; Paolina Salamone; Giuseppe Fuda; Carlo Colosimo; Cristina Spera; Prabha Cristina Ranchicchio; Giuseppe Stipa; Domenico Frondizi; Christian Lunetta; Valeria Sansone; Claudia Tarlarini; Francesca Gerardi; Vincenzo Silani; Alberto Doretti; Eleonora Colombo; Gianluca Demirtzidis; Gioacchino Tedeschi; Francesca Trojsi; Carla Passaniti; Stefania Ballestrero; Johannes Dorst; Ulrike Weiland; Andrea Fromm; Maximilian Wiesenfarth; Katharina Kandler; Simon Witzel; Markus Otto; Joachim Schuster; Thomas Meyer; André Maier; Dagmar Kettemann; Susanne Petri; Lars Müschen; Camilla Wohnrade; Anastasia Sarikidi; Alma Osmanovic; Julian Grosskreutz; Annekathrin Rödiger; Robert Steinbach; Benjamin Ilse; Uta Smesny; Robert Untucht; René Günther; Maximilian Vidovic; Pamela Shaw; Alexis Collins; Helen Wollff; Theresa Walsh; Lee Tuddenham; Mbombe Kazoka; David White; Stacy Young; Benjamin Thompson; Daniel Madarshahian; Suresh K. Chhetri; Amina Chaouch; Carolyn A. Young; Heike Arndt; Oliver C Hanemann; Thomas Lambert; Stephane Beltran; Philippe Couratier; Florence Esselin; William Camu; Elisa De; La Cruz; Gwendal Lemasson; Pegah Masrori; Sinead Maguire; Liz Fogarty; Toyosi Atoyebi; Niamh Ní Obáin
Frontiers in Neurology, Vol 13 (2022)
Academic Journal
Lombardo FL; National Centre for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome, Italy. flavia.lombardo@iss.it.; Spila Alegiani S; National Center for Drug Research and Evaluation, Italian National Institute of Health, Rome, Italy.; Mayer F; National Center for Drug Research and Evaluation, Italian National Institute of Health, Rome, Italy.; Cipriani M; Department of Statistical Sciences, Sapienza University of Rome, Rome, Italy.; Department of Neuroscience, Italian National Institute of Health, Rome, Italy.; Lo Giudice M; Neurology Department, IRCCS Humanitas Research Hospital, Rozzano, Italy.; Ludolph AC; Neurology Department, University of Ulm, Ulm, Germany.; German Centre of Neurodegenerative Diseases, Site Ulm, Ulm, Germany.; McDermott CJ; Department of Neuroscience, Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.; Corcia P; Centre de Référence Maladie Rare (CRMR) SLA Et Les Autres Maladies du Neurone Moteur (FILSLAN), Tours, France.; CHU Bretonneau, Tours, France.; Federation des CRMR-SLA Tours-Limoges, LITORALS, Tours, France.; Faculté de Médecine, INSERM U1253, 'iBrain,' Université François-Rabelais de Tours, Tours, France.; Van Damme P; Neurology Department, University Hospitals Leuven, Louvain, Belgium.; Neuroscience Department, KU Leuven, Louvain, Belgium.; Van den Berg LH; Department of Neurology, UMC Utrecht Brain Center, University Medical Centre Utrecht, Utrecht, Netherlands.; Hardiman O; Academic Unit of Neurology, Trinity Biomedical Sciences Institute, Dublin, Ireland.; Clinical Research Centre, Beaumont Hospital, Dublin, Ireland.; Nicolini G; Medical Affairs, Bruschettini S.R.L, Genoa, Italy.; Vanacore N; National Centre for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome, Italy.; Dickie B; Motor Neurone Disease Association, Northampton, UK.; Albanese A; Neurology Department, IRCCS Humanitas Research Hospital, Rozzano, Italy.; Puopolo M; Department of Neuroscience, Italian National Institute of Health, Rome, Italy.
Publisher: BioMed Central Country of Publication: England NLM ID: 101263253 Publication Model: Electronic Cited Medium: Internet ISSN: 1745-6215 (Electronic) Linking ISSN: 17456215 NLM ISO Abbreviation: Trials Subsets: MEDLINE
Academic Journal
Albanese A; Neurology Department, IRCCS Humanitas Research Hospital, Rozzano, Italy.; Ludolph AC; Neurology Department, University of Ulm, Ulm, Germany.; German Centre of Neurodegenerative Diseases, Site Ulm, Ulm, Germany.; McDermott CJ; Department of Neuroscience, Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, United Kingdom.; Corcia P; Centre de Référence Maladie Rare (CRMR) SLA et les autres maladies du neurone moteur (FILSLAN), Tours, France.; CHU Bretonneau, Tours, France.; Federation des CRMR-SLA Tours-Limoges, LITORALS, Tours, France.; INSERM U1253, 'iBrain,' Université François-Rabelais de Tours, Faculté de Médecine, Tours, France.; Van Damme P; Neurology Department, University Hospitals Leuven and Neuroscience Department, KU Leuven, Leuven, Belgium.; Van den Berg LH; Department of Neurology, UMC Utrecht Brain Center, University Medical Centre Utrecht, Utrecht, Netherlands.; Hardiman O; Academic Unit of Neurology, Trinity Biomedical Sciences Institute, Dublin, Ireland.; Clinical Research Centre, Beaumont Hospital, Dublin, Ireland.; Rinaldi G; Scientific Service, Bruschettini S.R.L, Genova, Italy.; Vanacore N; National Centre for Disease Prevention and Health Promotion, National Institute of Health, Rome, Italy.; Dickie B; Motor Neurone Disease Association, Northampton, United Kingdom.
Publisher: Frontiers Research Foundation Country of Publication: Switzerland NLM ID: 101546899 Publication Model: eCollection Cited Medium: Print ISSN: 1664-2295 (Print) Linking ISSN: 16642295 NLM ISO Abbreviation: Front Neurol Subsets: PubMed not MEDLINE
Report
University of Ulm; University of Sheffield; University Hospital, Tours; KU Leuven; UMC Utrecht; University of Dublin, Trinity College; Bruschettini S.r.l.; Istituto Superiore di Sanità; Motor Neurone Disease Association; European Commission
Albanese A, Ludolph AC, McDermott CJ, Corcia P, Van Damme P, Van den Berg LH, Hardiman O, Rinaldi G, Vanacore N, Dickie B; TUDCA -ALS Study Group . Tauroursodeoxycholic acid in patients with amyotrophic lateral sclerosis: The TUDCA -ALS trial protocol. Front Neurol. 2022 Sep 27;13:1009113. doi: 10.3389/fneur.2022.1009113. eCollection 2022.
Safety and Efficacy of Tauroursodeoxycholic (TUDCA ) as add-on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis (ALS )
Safety and Efficacy of Tauroursodeoxycholic (
Report
Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Dec;1(5):293-9. doi: 10.1080/146608200300079536. No abstract available.
Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A. The ALSFRS-R: a revisedALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999 Oct 31;169(1-2):13-21. doi: 10.1016/s0022-510x(99)00210-5.
Leigh PN, Swash M, Iwasaki Y, Ludolph A, Meininger V, Miller RG, Mitsumoto H, Shaw P, Tashiro K, Van Den Berg L. Amyotrophic lateral sclerosis: a consensus viewpoint on designing and implementing a clinical trial. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Jun;5(2):84-98. doi: 10.1080/14660820410020187.
Keene CD, Rodrigues CM, Eich T, Chhabra MS, Steer CJ, Low WC. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10671-6. doi: 10.1073/pnas.162362299. Epub 2002 Jul 29.
Benz C, Angermuller S, Otto G, Sauer P, Stremmel W, Stiehl A. Effect of tauroursodeoxycholic acid on bile acid-induced apoptosis in primary human hepatocytes. Eur J Clin Invest. 2000 Mar;30(3):203-9. doi: 10.1046/j.1365-2362.2000.00615.x.
Schoemaker MH, Conde de la Rosa L, Buist-Homan M, Vrenken TE, Havinga R, Poelstra K, Haisma HJ, Jansen PL, Moshage H. Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways. Hepatology. 2004 Jun;39(6):1563-73. doi: 10.1002/hep.20246.
Miller SD, Greene CM, McLean C, Lawless MW, Taggart CC, O'Neill SJ, McElvaney NG. Tauroursodeoxycholic acid inhibits apoptosis induced by Z alpha-1 antitrypsin via inhibition of Bad. Hepatology. 2007 Aug;46(2):496-503. doi: 10.1002/hep.21689.
Rodrigues CM, Sola S, Sharpe JC, Moura JJ, Steer CJ. Tauroursodeoxycholic acid prevents Bax-induced membrane perturbation and cytochrome C release in isolated mitochondria. Biochemistry. 2003 Mar 18;42(10):3070-80. doi: 10.1021/bi026979d.
Ramalho RM, Ribeiro PS, Sola S, Castro RE, Steer CJ, Rodrigues CM. Inhibition of the E2F-1/p53/Bax pathway by tauroursodeoxycholic acid in amyloid beta-peptide-induced apoptosis of PC12 cells. J Neurochem. 2004 Aug;90(3):567-75. doi: 10.1111/j.1471-4159.2004.02517.x.
Rodrigues CM, Sola S, Nan Z, Castro RE, Ribeiro PS, Low WC, Steer CJ. Tauroursodeoxycholic acid reduces apoptosis and protects against neurological injury after acute hemorrhagic stroke in rats. Proc Natl Acad Sci U S A. 2003 May 13;100(10):6087-92. doi: 10.1073/pnas.1031632100. Epub 2003 Apr 29.
Ramalho RM, Borralho PM, Castro RE, Sola S, Steer CJ, Rodrigues CM. Tauroursodeoxycholic acid modulates p53-mediated apoptosis in Alzheimer's disease mutant neuroblastoma cells. J Neurochem. 2006 Sep;98(5):1610-8. doi: 10.1111/j.1471-4159.2006.04007.x.
Ved R, Saha S, Westlund B, Perier C, Burnam L, Sluder A, Hoener M, Rodrigues CM, Alfonso A, Steer C, Liu L, Przedborski S, Wolozin B. Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of alpha-synuclein, parkin, and DJ-1 in Caenorhabditis elegans. J Biol Chem. 2005 Dec 30;280(52):42655-42668. doi: 10.1074/jbc.M505910200. Epub 2005 Oct 19.
Sola S, Castro RE, Laires PA, Steer CJ, Rodrigues CM. Tauroursodeoxycholic acid prevents amyloid-beta peptide-induced neuronal death via a phosphatidylinositol 3-kinase-dependent signaling pathway. Mol Med. 2003 Sep-Dec;9(9-12):226-34. doi: 10.2119/2003-00042.rodrigues.
Rudolph G, Kloeters-Plachky P, Sauer P, Stiehl A. Intestinal absorption and biliary secretion of ursodeoxycholic acid and its taurine conjugate. Eur J Clin Invest. 2002 Aug;32(8):575-80. doi: 10.1046/j.1365-2362.2002.01030.x.
Keene CD, Rodrigues CM, Eich T, Linehan-Stieers C, Abt A, Kren BT, Steer CJ, Low WC. A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease. Exp Neurol. 2001 Oct;171(2):351-60. doi: 10.1006/exnr.2001.7755.
Castro RE, Sola S, Ramalho RM, Steer CJ, Rodrigues CM. The bile acid tauroursodeoxycholic acid modulates phosphorylation and translocation of bad via phosphatidylinositol 3-kinase in glutamate-induced apoptosis of rat cortical neurons. J Pharmacol Exp Ther. 2004 Nov;311(2):845-52. doi: 10.1124/jpet.104.070532. Epub 2004 Jun 9.
Ince PG, Tomkins J, Slade JY, Thatcher NM, Shaw PJ. Amyotrophic lateral sclerosis associated with genetic abnormalities in the gene encoding Cu/Zn superoxide dismutase: molecular pathology of five new cases, and comparison with previous reports and 73 sporadic cases ofALS . J Neuropathol Exp Neurol. 1998 Oct;57(10):895-904. doi: 10.1097/00005072-199810000-00002.
Chaudhuri KR, Crump S, al-Sarraj S, Anderson V, Cavanagh J, Leigh PN. The validation of El Escorial criteria for the diagnosis of amyotrophic lateral sclerosis: a clinicopathologicalstudy . J Neurol Sci. 1995 May;129 Suppl:11-2. doi: 10.1016/0022-510x(95)00050-c. No abstract available.
Turner MR, Bakker M, Sham P, Shaw CE, Leigh PN, Al-Chalabi A. Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002 Mar;3(1):15-21. doi: 10.1080/146608202317576499.
Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death inALS . Nat Rev Neurosci. 2001 Nov;2(11):806-19. doi: 10.1038/35097565. No abstract available.
Shaw CE, al-Chalabi A, Leigh N. Progress in the pathogenesis of amyotrophic lateral sclerosis. Curr Neurol Neurosci Rep. 2001 Jan;1(1):69-76. doi: 10.1007/s11910-001-0078-7.
Heath PR, Shaw PJ. Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve. 2002 Oct;26(4):438-58. doi: 10.1002/mus.10186.
Sathasivam S, Ince PG, Shaw PJ. Apoptosis in amyotrophic lateral sclerosis: a review of the evidence. Neuropathol Appl Neurobiol. 2001 Aug;27(4):257-74. doi: 10.1046/j.0305-1846.2001.00332.x.
Rizzardini M, Lupi M, Bernasconi S, Mangolini A, Cantoni L. Mitochondrial dysfunction and death in motor neurons exposed to the glutathione-depleting agent ethacrynic acid. J Neurol Sci. 2003 Mar 15;207(1-2):51-8. doi: 10.1016/s0022-510x(02)00357-x.
Robertson J, Kriz J, Nguyen MD, Julien JP. Pathways to motor neuron degeneration in transgenic mouse models. Biochimie. 2002 Nov;84(11):1151-60. doi: 10.1016/s0300-9084(02)00025-1.
Rosen DR. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993 Jul 22;364(6435):362. doi: 10.1038/364362c0. No abstract available.
Shaw CE, Enayat ZE, Chioza BA, Al-Chalabi A, Radunovic A, Powell JF, Leigh PN. Mutations in all five exons of SOD-1 may causeALS . Ann Neurol. 1998 Mar;43(3):390-4. doi: 10.1002/ana.410430319.
Yang Y, Hentati A, Deng HX, Dabbagh O, Sasaki T, Hirano M, Hung WY, Ouahchi K, Yan J, Azim AC, Cole N, Gascon G, Yagmour A, Ben-Hamida M, Pericak-Vance M, Hentati F, Siddique T. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat Genet. 2001 Oct;29(2):160-5. doi: 10.1038/ng1001-160.
Puls I, Jonnakuty C, LaMonte BH, Holzbaur EL, Tokito M, Mann E, Floeter MK, Bidus K, Drayna D, Oh SJ, Brown RH Jr, Ludlow CL, Fischbeck KH. Mutant dynactin in motor neuron disease. Nat Genet. 2003 Apr;33(4):455-6. doi: 10.1038/ng1123. Epub 2003 Mar 10.
Al-Chalabi A, Andersen PM, Nilsson P, Chioza B, Andersson JL, Russ C, Shaw CE, Powell JF, Leigh PN. Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. Hum Mol Genet. 1999 Feb;8(2):157-64. doi: 10.1093/hmg/8.2.157.
Friedlander RM. Apoptosis and caspases in neurodegenerative diseases. N Engl J Med. 2003 Apr 3;348(14):1365-75. doi: 10.1056/NEJMra022366. No abstract available.
Waldmeier PC. Prospects for antiapoptotic drug therapy of neurodegenerative diseases. Prog Neuropsychopharmacol Biol Psychiatry. 2003 Apr;27(2):303-21. doi: 10.1016/S0278-5846(03)00025-3.
Worms PM. The epidemiology of motor neuron diseases: a review of recentstudies . J Neurol Sci. 2001 Oct 15;191(1-2):3-9. doi: 10.1016/s0022-510x(01)00630-x.
Mandrioli J, Faglioni P, Merelli E, Sola P. The epidemiology ofALS in Modena, Italy. Neurology. 2003 Feb 25;60(4):683-9. doi: 10.1212/01.wnl.0000048208.54755.78.
Emery AE, Holloway S. Familial motor neuron diseases. Adv Neurol. 1982;36:139-47. No abstract available.
Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis.ALS /Riluzole Study Group . N Engl J Med. 1994 Mar 3;330(9):585-91. doi: 10.1056/NEJM199403033300901.
Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-rangingstudy of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996 May 25;347(9013):1425-31. doi: 10.1016/s0140-6736(96)91680-3.
Orrell RW, Lane RJ, Ross M. Antioxidant treatment for amyotrophic lateral sclerosis / motor neuron disease. Cochrane Database Syst Rev. 2005 Jan 25;(1):CD002829. doi: 10.1002/14651858.CD002829.pub3.
Moore DH 2nd, Miller RG. Improving efficiency ofALS clinical trials using lead-in designs. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Sep;5 Suppl 1:57-60. doi: 10.1080/17434470410019997.
Miller RG, Munsat TL, Swash M, Brooks BR. Consensus guidelines for the design and implementation of clinical trials inALS . World Federation of Neurology committee on Research. J Neurol Sci. 1999 Oct 31;169(1-2):2-12. doi: 10.1016/s0022-510x(99)00209-9.
Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med. 2001 May 31;344(22):1688-700. doi: 10.1056/NEJM200105313442207. No abstract available.
A Randomized, Double-blind Multicenter PilotStudy vs. Placebo for the Evaluation of Efficacy and Tolerability of Tauroursodeoxycholic Acid Administered by Oral Route as Add on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis
Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A. The ALSFRS-R: a revised
Leigh PN, Swash M, Iwasaki Y, Ludolph A, Meininger V, Miller RG, Mitsumoto H, Shaw P, Tashiro K, Van Den Berg L. Amyotrophic lateral sclerosis: a consensus viewpoint on designing and implementing a clinical trial. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Jun;5(2):84-98. doi: 10.1080/14660820410020187.
Keene CD, Rodrigues CM, Eich T, Chhabra MS, Steer CJ, Low WC. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10671-6. doi: 10.1073/pnas.162362299. Epub 2002 Jul 29.
Benz C, Angermuller S, Otto G, Sauer P, Stremmel W, Stiehl A. Effect of tauroursodeoxycholic acid on bile acid-induced apoptosis in primary human hepatocytes. Eur J Clin Invest. 2000 Mar;30(3):203-9. doi: 10.1046/j.1365-2362.2000.00615.x.
Schoemaker MH, Conde de la Rosa L, Buist-Homan M, Vrenken TE, Havinga R, Poelstra K, Haisma HJ, Jansen PL, Moshage H. Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways. Hepatology. 2004 Jun;39(6):1563-73. doi: 10.1002/hep.20246.
Miller SD, Greene CM, McLean C, Lawless MW, Taggart CC, O'Neill SJ, McElvaney NG. Tauroursodeoxycholic acid inhibits apoptosis induced by Z alpha-1 antitrypsin via inhibition of Bad. Hepatology. 2007 Aug;46(2):496-503. doi: 10.1002/hep.21689.
Rodrigues CM, Sola S, Sharpe JC, Moura JJ, Steer CJ. Tauroursodeoxycholic acid prevents Bax-induced membrane perturbation and cytochrome C release in isolated mitochondria. Biochemistry. 2003 Mar 18;42(10):3070-80. doi: 10.1021/bi026979d.
Ramalho RM, Ribeiro PS, Sola S, Castro RE, Steer CJ, Rodrigues CM. Inhibition of the E2F-1/p53/Bax pathway by tauroursodeoxycholic acid in amyloid beta-peptide-induced apoptosis of PC12 cells. J Neurochem. 2004 Aug;90(3):567-75. doi: 10.1111/j.1471-4159.2004.02517.x.
Rodrigues CM, Sola S, Nan Z, Castro RE, Ribeiro PS, Low WC, Steer CJ. Tauroursodeoxycholic acid reduces apoptosis and protects against neurological injury after acute hemorrhagic stroke in rats. Proc Natl Acad Sci U S A. 2003 May 13;100(10):6087-92. doi: 10.1073/pnas.1031632100. Epub 2003 Apr 29.
Ramalho RM, Borralho PM, Castro RE, Sola S, Steer CJ, Rodrigues CM. Tauroursodeoxycholic acid modulates p53-mediated apoptosis in Alzheimer's disease mutant neuroblastoma cells. J Neurochem. 2006 Sep;98(5):1610-8. doi: 10.1111/j.1471-4159.2006.04007.x.
Ved R, Saha S, Westlund B, Perier C, Burnam L, Sluder A, Hoener M, Rodrigues CM, Alfonso A, Steer C, Liu L, Przedborski S, Wolozin B. Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of alpha-synuclein, parkin, and DJ-1 in Caenorhabditis elegans. J Biol Chem. 2005 Dec 30;280(52):42655-42668. doi: 10.1074/jbc.M505910200. Epub 2005 Oct 19.
Sola S, Castro RE, Laires PA, Steer CJ, Rodrigues CM. Tauroursodeoxycholic acid prevents amyloid-beta peptide-induced neuronal death via a phosphatidylinositol 3-kinase-dependent signaling pathway. Mol Med. 2003 Sep-Dec;9(9-12):226-34. doi: 10.2119/2003-00042.rodrigues.
Rudolph G, Kloeters-Plachky P, Sauer P, Stiehl A. Intestinal absorption and biliary secretion of ursodeoxycholic acid and its taurine conjugate. Eur J Clin Invest. 2002 Aug;32(8):575-80. doi: 10.1046/j.1365-2362.2002.01030.x.
Keene CD, Rodrigues CM, Eich T, Linehan-Stieers C, Abt A, Kren BT, Steer CJ, Low WC. A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease. Exp Neurol. 2001 Oct;171(2):351-60. doi: 10.1006/exnr.2001.7755.
Castro RE, Sola S, Ramalho RM, Steer CJ, Rodrigues CM. The bile acid tauroursodeoxycholic acid modulates phosphorylation and translocation of bad via phosphatidylinositol 3-kinase in glutamate-induced apoptosis of rat cortical neurons. J Pharmacol Exp Ther. 2004 Nov;311(2):845-52. doi: 10.1124/jpet.104.070532. Epub 2004 Jun 9.
Ince PG, Tomkins J, Slade JY, Thatcher NM, Shaw PJ. Amyotrophic lateral sclerosis associated with genetic abnormalities in the gene encoding Cu/Zn superoxide dismutase: molecular pathology of five new cases, and comparison with previous reports and 73 sporadic cases of
Chaudhuri KR, Crump S, al-Sarraj S, Anderson V, Cavanagh J, Leigh PN. The validation of El Escorial criteria for the diagnosis of amyotrophic lateral sclerosis: a clinicopathological
Turner MR, Bakker M, Sham P, Shaw CE, Leigh PN, Al-Chalabi A. Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002 Mar;3(1):15-21. doi: 10.1080/146608202317576499.
Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in
Shaw CE, al-Chalabi A, Leigh N. Progress in the pathogenesis of amyotrophic lateral sclerosis. Curr Neurol Neurosci Rep. 2001 Jan;1(1):69-76. doi: 10.1007/s11910-001-0078-7.
Heath PR, Shaw PJ. Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve. 2002 Oct;26(4):438-58. doi: 10.1002/mus.10186.
Sathasivam S, Ince PG, Shaw PJ. Apoptosis in amyotrophic lateral sclerosis: a review of the evidence. Neuropathol Appl Neurobiol. 2001 Aug;27(4):257-74. doi: 10.1046/j.0305-1846.2001.00332.x.
Rizzardini M, Lupi M, Bernasconi S, Mangolini A, Cantoni L. Mitochondrial dysfunction and death in motor neurons exposed to the glutathione-depleting agent ethacrynic acid. J Neurol Sci. 2003 Mar 15;207(1-2):51-8. doi: 10.1016/s0022-510x(02)00357-x.
Robertson J, Kriz J, Nguyen MD, Julien JP. Pathways to motor neuron degeneration in transgenic mouse models. Biochimie. 2002 Nov;84(11):1151-60. doi: 10.1016/s0300-9084(02)00025-1.
Rosen DR. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993 Jul 22;364(6435):362. doi: 10.1038/364362c0. No abstract available.
Shaw CE, Enayat ZE, Chioza BA, Al-Chalabi A, Radunovic A, Powell JF, Leigh PN. Mutations in all five exons of SOD-1 may cause
Yang Y, Hentati A, Deng HX, Dabbagh O, Sasaki T, Hirano M, Hung WY, Ouahchi K, Yan J, Azim AC, Cole N, Gascon G, Yagmour A, Ben-Hamida M, Pericak-Vance M, Hentati F, Siddique T. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat Genet. 2001 Oct;29(2):160-5. doi: 10.1038/ng1001-160.
Puls I, Jonnakuty C, LaMonte BH, Holzbaur EL, Tokito M, Mann E, Floeter MK, Bidus K, Drayna D, Oh SJ, Brown RH Jr, Ludlow CL, Fischbeck KH. Mutant dynactin in motor neuron disease. Nat Genet. 2003 Apr;33(4):455-6. doi: 10.1038/ng1123. Epub 2003 Mar 10.
Al-Chalabi A, Andersen PM, Nilsson P, Chioza B, Andersson JL, Russ C, Shaw CE, Powell JF, Leigh PN. Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. Hum Mol Genet. 1999 Feb;8(2):157-64. doi: 10.1093/hmg/8.2.157.
Friedlander RM. Apoptosis and caspases in neurodegenerative diseases. N Engl J Med. 2003 Apr 3;348(14):1365-75. doi: 10.1056/NEJMra022366. No abstract available.
Waldmeier PC. Prospects for antiapoptotic drug therapy of neurodegenerative diseases. Prog Neuropsychopharmacol Biol Psychiatry. 2003 Apr;27(2):303-21. doi: 10.1016/S0278-5846(03)00025-3.
Worms PM. The epidemiology of motor neuron diseases: a review of recent
Mandrioli J, Faglioni P, Merelli E, Sola P. The epidemiology of
Emery AE, Holloway S. Familial motor neuron diseases. Adv Neurol. 1982;36:139-47. No abstract available.
Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis.
Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging
Orrell RW, Lane RJ, Ross M. Antioxidant treatment for amyotrophic lateral sclerosis / motor neuron disease. Cochrane Database Syst Rev. 2005 Jan 25;(1):CD002829. doi: 10.1002/14651858.CD002829.pub3.
Moore DH 2nd, Miller RG. Improving efficiency of
Miller RG, Munsat TL, Swash M, Brooks BR. Consensus guidelines for the design and implementation of clinical trials in
Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med. 2001 May 31;344(22):1688-700. doi: 10.1056/NEJM200105313442207. No abstract available.
A Randomized, Double-blind Multicenter Pilot
검색 결과 제한하기
제한된 항목
[검색어] TUDCA-ALS Study Group
발행연도 제한
-
학술DB(Database Provider)
저널명(출판물, Title)
출판사(Publisher)
자료유형(Source Type)
주제어
언어